Common Contracts
5 similar Chef Purchase Agreement contracts by Senti Biosciences, Inc., Allurion Technologies, Inc., Better Therapeutics, Inc., Sonnet BioTherapeutics Holdings, Inc.
AMENDED AND RESTATED ChEF PURCHASE AGREEMENTChef Purchase Agreement • July 16th, 2024 • Senti Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
statements and other information attached thereto or incorporated by reference therein as Exhibits thereto (as amended, the “Merger Form 8-K”), (2) the Company’s registration statement on Form S-4 (File No. 333-262707) initially filed with the Commission on February 14, 2022, including any related prospectus or prospectuses, for the registration of the Common Stock to be issued pursuant to the Business Combination Agreement by and among Senti Sub I, Inc. (formerly Senti Biosciences, Inc.), Explore Merger Sub, Inc. and Dynamics Special Purpose Corp., on file with the Commission at the time such registration statement became effective, including the financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information deemed to be a part thereof as of the effective date of such registration statement under the Securities Act (the “Company Form S-4 Registration Statement”), (3) the Company’s proxy statement/prospectus, dated
ChEF PURCHASE AGREEMENTChef Purchase Agreement • May 3rd, 2024 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations • New York
This ChEF PURCHASE AGREEMENT is made and entered into as of May 2, 2024 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”).
ChEF PURCHASE AGREEMENTChef Purchase Agreement • December 19th, 2023 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • New York
This ChEF PURCHASE AGREEMENT is made and entered into as of December 18, 2023 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Allurion Technologies, Inc., a Delaware corporation (the “Company”).
ChEF PURCHASE AGREEMENTChef Purchase Agreement • December 13th, 2023 • Better Therapeutics, Inc. • Services-health services • New York
This ChEF PURCHASE AGREEMENT is made and entered into as of December 13, 2023 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Better Therapeutics, Inc., a Delaware corporation (the “Company”).
ChEF PURCHASE AGREEMENTChef Purchase Agreement • September 1st, 2022 • Senti Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
This ChEF PURCHASE AGREEMENT is made and entered into as of August 31, 2022 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Senti Biosciences, Inc., a Delaware corporation (the “Company”).
